MDT

101.85

+2.05%↑

A

139.48

+1.36%↑

VEEV

222.48

+1.7%↑

HQY

87.09

+2.94%↑

NEOG

9.97

+3.96%↑

MDT

101.85

+2.05%↑

A

139.48

+1.36%↑

VEEV

222.48

+1.7%↑

HQY

87.09

+2.94%↑

NEOG

9.97

+3.96%↑

MDT

101.85

+2.05%↑

A

139.48

+1.36%↑

VEEV

222.48

+1.7%↑

HQY

87.09

+2.94%↑

NEOG

9.97

+3.96%↑

MDT

101.85

+2.05%↑

A

139.48

+1.36%↑

VEEV

222.48

+1.7%↑

HQY

87.09

+2.94%↑

NEOG

9.97

+3.96%↑

MDT

101.85

+2.05%↑

A

139.48

+1.36%↑

VEEV

222.48

+1.7%↑

HQY

87.09

+2.94%↑

NEOG

9.97

+3.96%↑

Search

CareDx Inc

Open

SectorGezondheidszorg

21.13 2.72

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

20.39

Max

21.43

Belangrijke statistieken

By Trading Economics

Inkomsten

10M

1.7M

Verkoop

13M

100M

K/W

Sectorgemiddelde

15.633

89.037

Winstmarge

1.674

Werknemers

644

EBITDA

11M

6.8M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

-10.89% downside

Dividenden

By Dow Jones

Volgende Winsten

25 feb 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

279M

1.1B

Vorige openingsprijs

18.41

Vorige sluitingsprijs

21.13

Nieuwssentiment

By Acuity

50%

50%

177 / 360 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Neutral Evidence

CareDx Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

21 jan 2026, 23:49 UTC

Belangrijke Marktbewegers

Karman Space & Defense Shares Rise as 2026 Forecast Tops Analyst Estimates

21 jan 2026, 21:12 UTC

Belangrijke Marktbewegers

Automaker Stocks Rise After Trump Calls Off European Tariffs

21 jan 2026, 21:00 UTC

Acquisities, Fusies, Overnames

Deutsche Borse Group to Acquire Allfunds for $6.19 Billion

21 jan 2026, 20:29 UTC

Belangrijke Marktbewegers

Chip Makers Gain After Trump Calls Off European Tariffs

21 jan 2026, 20:04 UTC

Belangrijke Marktbewegers

Apparel, Footwear Stocks Rise After Trump Calls Off European Tariffs

21 jan 2026, 23:48 UTC

Marktinformatie

Nikkei May Rise as U.S.-Europe Tensions Ease -- Market Talk

21 jan 2026, 23:34 UTC

Marktinformatie

Gold Falls Amid Easing U.S.-Europe Tensions Over Greenland -- Market Talk

21 jan 2026, 22:39 UTC

Winsten

Schwab's Profit Jumps on Surge in Brokerage Activity -- 2nd Update

21 jan 2026, 21:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

21 jan 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

21 jan 2026, 21:35 UTC

Acquisities, Fusies, Overnames

Tesla Stock In Focus as Musk and Ryanair Chief Trade Insults. Should Investors Worry? -- Barrons.com

21 jan 2026, 21:19 UTC

Winsten

Charles Schwab Earnings Miss Estimates. The Stock Is Rising Anyway. -- Barrons.com

21 jan 2026, 20:45 UTC

Acquisities, Fusies, Overnames

Deutsche Borse Group to Acquire Allfunds for $6.19B

21 jan 2026, 20:36 UTC

Marktinformatie

U.S. Natural Gas Posts Back-to-Back Hefty Gains -- Market Talk

21 jan 2026, 20:31 UTC

Marktinformatie

Oil Settles Higher With Support From Heating Fuel -- Market Talk

21 jan 2026, 20:27 UTC

Acquisities, Fusies, Overnames

Deutsche Boerse Expects Combined Company Will Be Able to Achieve Annual Run Rate Pretax Cost Synergies of About EUR60M

21 jan 2026, 20:27 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

21 jan 2026, 20:27 UTC

Marktinformatie

Was It a 'TACO' Event? -- Market Talk

21 jan 2026, 20:26 UTC

Acquisities, Fusies, Overnames

Deutsche Boerse Has Received Irrevocable Undertakings in Support of Acquisition in Respect of About 48.9% of Allfunds Issued Share Capital Excluding Treasury Shares

21 jan 2026, 20:23 UTC

Acquisities, Fusies, Overnames

Deutsche Boerse: Allfunds Stockholders to Receive EUR8.80/Shr, Including Cash, Stock and Permitted Dividend

21 jan 2026, 20:21 UTC

Acquisities, Fusies, Overnames

Deutsche Boerse: Agreement Values Allfunds at About EUR5.3B

21 jan 2026, 20:19 UTC

Acquisities, Fusies, Overnames

Deutsche Boerse Group Agrees to Buy Allfunds

21 jan 2026, 20:08 UTC

Winsten

Prologis Revenue Climbs as Warehouse Demand Rebounds -- Update

21 jan 2026, 20:03 UTC

Marktinformatie

Precious Metals Drop After Trump Posts About Greenland Deal -- Market Talk

21 jan 2026, 19:51 UTC

Marktinformatie

Treasury Markets React to Trump's Softer Tone About Greenland -- Market Talk

21 jan 2026, 19:43 UTC

Marktinformatie

U.S. Ethanol Production Expected to Slip -- Market Talk

21 jan 2026, 19:31 UTC

Marktinformatie

Gold Settles at Fresh All-Time High -- Market Talk

21 jan 2026, 19:24 UTC

Winsten

Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. -- Barrons.com

21 jan 2026, 19:10 UTC

Marktinformatie

Mexican Inflation Seen Picking Up in Early January -- Market Talk

21 jan 2026, 18:57 UTC

Marktinformatie

DAVOS: IBM CEO Krishna Says World Is More Volatile Now -- Market Talk

Peer Vergelijking

Prijswijziging

CareDx Inc Prognose

Koersdoel

By TipRanks

-10.89% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 18 USD  -10.89%

Hoogste 18 USD

Laagste 18 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor CareDx Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

4 ratings

1

Buy

3

Hold

0

Sell

Technische score

By Trading Central

14.77 / 18.49Steun & Weerstand

Korte Termijn

Neutral Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

177 / 360 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
help-icon Live chat